RxDoctor Payments Data

Adam Goldberg, MD

Clinical Cardiac Electrophysiology · Charlottesville, VANPI 1346437241

Payments from drug & device makers

$4,938in general payments, 2019–2025

Across 100 payments — averaging $49.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$741
  • Boston Scientific$685
  • Cvrx, Inc.$120
  • Johnson & Johnson$69
  • AstraZeneca$26

What the payments were for

  • Travel & lodging$49110%
  • Food & beverage$4,42190%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)68$3,297
Abbott8$741
Boston Scientific19$685
Cvrx, Inc.2$120
Johnson & Johnson1$69
AstraZeneca2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,938 in reported general payments places this provider in the 10th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

See all clinical cardiac electrophysiology providers in Virginia

Medicare billing

Part B allowed, 2024
$523,161
Medicare patients
2,101
Services billed
6,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban657$728,539
XareltoRivaroxaban112$121,143
Dofetilide166$25,910
EntrestoSacubitril/Valsartan12$20,659
BrilintaTicagrelor23$14,695
Flecainide Acetate158$7,468
Metoprolol Succinate371$4,397
Dabigatran EtexilateDabigatran Etexilate Mesylate12$3,902
Amiodarone Hcl58$1,041
Carvedilol104$928
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$920
Torsemide30$784
SotalolSotalol Hcl50$752
Losartan Potassium91$679
Metoprolol Tartrate97$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$69$121,143112 claims
AstraZenecaBrilinta$26$14,69523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

Other clinical cardiac electrophysiology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →